Bladder Health Week is a welcome reminder of the efforts urology researchers make to expand and improve patients’ treatment options for bladder diseases. 

Bladder cancer is but one of many diseases that affect the urinary system.  Conditions like interstitial cystitis (IC) and bladder pain syndrome (BPS) are painful illnesses that can seriously impact one’s health and happiness.  Overactive bladder, nocturia, and urinary incontinence can disrupt sleep, make everyday tasks difficult, and have a devastating impact on one’s social life.  In many cases, bladder conditions can lead to problems in professional and personal relationships.

October 29 is World Psoriasis Day, a time to raise awareness of a chronic condition affecting millions worldwide.  The facts are striking – nearly 3 percent of the world’s population has psoriasis.

BIGFORK, Montana and KITCHENER Ontario, Canada, Swan Valley Medical, Incorporated, together with St. Mary’s General Hospital announced that the T-SPeC® Surgical System was used in its first live human clinical cases on August 15, 2012, for the treatment of chronic urinary retention and to evaluate patient comfort and improved safety.

Dermatolgoist Dr. Michael Freeman is among many clinical trial sites in Australia beginning new clinical trials for psoriasis this year.

Probity Medical Research Inc. (PMR), a leading provider of clinical research support services, welcomes Dr. Mark Lomaga, BScPhm, PhD, MD, DABD, FRCPC and Dr. Firouzeh Niakosari, MD, FCAP, FRCPC (Pathology and Dermatology) and their dermatology research team in Mississauga, Ontario, Canada.

Probity Medical Research Inc. (PMR), a leading provider of clinical research support services, welcomes Dr. Diana Rubel, MB BS, Dip Paeds, M Med, FACD to PMR's international network of Dermatology clinical trial sites.

Clinical Research Company, Probity Medical Research Inc. (PMR) announced today the appointment of Dr. R. Blair Egerdie as the Director of Urology, effective October 17, 2011.

Novartis has announced positive results from three Phase II trials showing that AIN457 (secukinumab) produced a quick and significant improvement of symptoms in patients with moderate-to-severe plaque psoriasis.

Clinical research company, Probity Medical Research Inc. (PMR), re-launched ResearchTrials.org, the online portal to connect patients with medical researchers in Canada, the US and Australia.

Probity Medical Research Inc. (PMR) a leading provider of clinical research support services has expanded clinical research activity by launching operations in Australia...